rsv arexvy - Search News

Order byBest matchMost fresh

News

GSK, RSV and European Medicines Agency

· 2d · on MSN

GSK says EU regulator reviewing expanded use of RSV vaccine

GSK said on Friday the European Medicines Agency had accepted the drugmaker's application to expand the use of its respiratory syncytial virus (RSV) vaccine, Arexvy, to adults aged 18 and above. An expanded approval will help GSK better compete with rivals such as Merck's mRESVIA and Pfizer's Abrysvo after U.

Continue reading

Medical Dialogues · 1d

GSK RSV vaccine Arexvy accepted for regulatory review by EMA to expand use in adults 18 years, older

GSK (LSE:GSK) Seeks European Expansion Of RSV Vaccine To Adults 18 And Older

2d

FDA clears Moderna’s RSV vaccine for use in people ages 18 to 59

The Food and Drug Administration expanded the approval of Moderna’s RSV vaccine on Thursday, extending the license to include ...

FDA clears Moderna’s RSV vaccine for use in people aged 18 to 59

The FDA expanded the approval of Moderna’s RSV vaccine, extending the license to include more adults and giving the company a ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results